NeurologyLive® Friday 5 — October 10, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Phase 1b Interim Data on GT-02287 in Parkinson Disease: Jonas Hannestad, MD, PhD

The chief medical officer of Gain Therapeutics discusses GT-02287, a promising treatment for Parkinson that has shown strong safety and tolerability in an ongoing phase 1 trial. [WATCH TIME: 3 minutes]

2: Navigating the Patient Decision to Pursue Huntington Disease Testing: Veronica Santini, MD, MA

The chief of the Movement Disorders Division at Yale School of Medicine discusses the nuance around patient choice in Huntington disease testing and providing treatment regardless of confirmation. [WATCH TIME: 3 minutes]

3: Protein Waste Clearance in Aging and Neurodegeneration: Lorraine Kalia, MD, PhD

The associate professor and clinician-scientist at the University of Toronto spoke to the current understanding of protein waste clearance in neurodegeneration. [WATCH TIME: 4 minutes]

4: NeuroVoices: A. Jon Stoessl, MD, on Understanding Plasticity and Disease Trajectory in Parkinson Disease

In our latest NeuroVoices Q&A, the neurologist at University of British Columbia discussed how abnormal brain plasticity influences Parkinson progression and highlighted the importance of integrating basic science with clinical care.

5: Overviewing Early-Stage Efficacy, Safety Data of Zorevunersen

Epileptologist Scott Perry, MD, reviews findings from the early-phase Monarch and Admiral trials, highlighting zorevunersen’s dose-response profile, seizure reduction, and safety outcomes. [WATCH TIME: 3 minutes]